In a case of consolidation in the Chinese pharma sector, LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million. Under the terms of the deal ...

Ashlyn is one of Forbes Home's in-house writers and a former civil engineer-turned content writer with over six years experience. Until recently, Ashlyn focused on creating content for Forbes Home as ...